Kelly M. Brady

Kelly Brady is the Vice President of Clinical Operations at Seres. Throughout her 13-year career she has held positions of increasing responsibility in clinical operations and clinical program management. Prior to joining Seres, Kelly was Senior Director and Global Clinical Program Lead at Akebia, where she oversaw pivotal programs in anemia due to chronic kidney disease. She also previously held roles in Operations and Program management at Acetylon, where she worked on the company’s acquisition by Celgene. Prior to Acetylon, she was the Global Phase 3 Clinical Operations Leader at Millennium Pharmaceuticals at Takeda, overseeing the Adcetris trials in Hodgkins Lymphoma across 29 countries. She also worked as a member of the operations team at Osiris Therapeutics, managing global GVHD studies and working on the stem cell therapy, Prochymal. Kelly holds a Bachelor’s degree in Neuroscience from Lafayette College and a Master’s degree in Biotechnology from Johns Hopkins University.